Effective, but expensive
Experimental drug for obesity allows you to lose more than 20% of body weight
Eli Lilly has released a press release with data from clinical trials of tirzepatide, an anti-obesity drug that can become an alternative to bariatric surgery. There is no publication in the peer-reviewed journal yet, but the comments of experts and industry analysts are very optimistic.
Phase 3 of the SURMOUNT-1 study involved 2,539 obese or overweight people (104.8 kg on average) and at least one concomitant disease, but without diabetes. Participants took Tirzepatide at doses of 5, 10, 15 mg for 72 weeks; 63% of the group with the maximum dosage reduced body weight by 20% or more. The average decrease in the 5 mg group was 16% (16 kg), in the 10 mg group — 21.4% (22 kg), in the 15 mg group — 22.5% (24 kg). Those who took higher doses weighed about 81.6 kg on average at the end of the study.
Tirzepatide is an agonist of hormone receptors of incretins that stimulate insulin secretion: GIP (glucose—dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). As shown in preclinical studies, it reduces food intake and increases energy consumption.
However, tirzepatide, obviously, will need to be taken for life, comments The New York Times, and it's sure to be expensive. Novo Nordisk's competitive Vegovi (semaglutide) drug costs $1,349.02 per month. At the same time, it is unclear whether it will be possible to get insurance compensation for it.
Portal "Eternal youth" http://vechnayamolodost.ru